Discover 260 paid clinical trials in Spokane, Washington. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 260
Active & Responsive
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
for
Parkinson's Disease (PD)
Location: 30 recruiting locations
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06107426
Recruiting
Active & Responsive
A Study of RSLV-132 in Females With Sjögren's Disease
for
Primary Sjögren Syndrome
Location: 23 recruiting locations
Sponsor: Resolve Therapeutics
Sex: Female
Age: 18 - 70+
Code: NCT06440525
Phase2, Recruiting
Active & Responsive
Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
for
Age-Related Macular Degeneration
Location: 11 recruiting locations
Sponsor: Astellas Institute for Regenerative Medicine
Sex: All
Age: 50+
Code: NCT03178149
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Belimumab With Rituximab for Primary Membranous Nephropathy
for
Membranous Nephropathy, Nephrotic Syndrome
Location: 20 recruiting locations
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sex: All
Age: 18 - 70+
Code: NCT03949855
Phase2, Recruiting
Active & Responsive
Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach
for
Interaction
Location: 1 recruiting location
Sponsor: Washington State University
Sex: All
Age: 18 - 64
Code: NCT06693960
Early_phase1, Recruiting
Active & Responsive
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)